A Double-blind, Randomized, Intra-subject Placebo-controlled, Multicenter, Multiple Dose Study, Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With Confirmed DDEB or RDEB Diagnosis With One or More Pathogenic Mutations in Exon 73 in the COL7A1 Gene

NCT ID: NCT03605069

Last Updated: 2021-08-25

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 2 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-07-02
• Study Completion Date: 2018-12-17

Brief Summary

A double-blind, randomized, intra-subject placebo-controlled, multicenter, multiple dose study, evaluating safety, proof of mechanism, preliminary efficacy and systemic exposure in subjects with confirmed DDEB or RDEB diagnosis with one or more pathogenic mutations in exon 73 in the COL7A1 gene.

Detailed Description

This clinical trial will evaluate the safety and tolerability, proof of mechanism, systemic exposure and preliminary efficacy following topical application of QR-313 to subjects with confirmed DDEB or RDEB with one or more pathogenic mutations in exon 73 in the COL7A1 gene.

Up to two Target Wound Areas (TWAs) per subject will be selected and randomized. Each TWA will be treated with IMP for 8 weeks, either QR-313 or matching placebo. All subjects will continue to be followed up for 8 weeks post last dose.

Subjects will be monitored through home visits and site visits. An imaging system will be used to assess the target wound at all home and study site visits.

QR-313 is a 21-nucleotide antisense oligonucleotide (AON) designed to hybridize to a specific sequence in the COL7A1 pre-messengerRNA (pre-mRNA).

Conditions

Epidermolysis Bullosa Dystrophica, Recessive; Epidermolysis Bullosa Dystrophica, Dominant

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

First TWA (A)

In each subject up to two target wound areas (TWA) are randomized, one each to active treatment or placebo.

In the first arm; randomization of the first selected TWA to active treatment or placebo

Group Type: OTHER

QR-313

Intervention Type: DRUG

QR-313 will be applied topically once daily for 8 weeks of treatment.

Placebo

Intervention Type: DRUG

Placebo will be applied topically once daily for 8 weeks of treatment.

Second TWA (B)

In each subject, in the second arm; allocation of the second selected target wound area (TWA) to the alternative treatment. Second arm in the same subject as the first arm.

Group Type: OTHER

QR-313

Intervention Type: DRUG

QR-313 will be applied topically once daily for 8 weeks of treatment.

Placebo

Intervention Type: DRUG

Placebo will be applied topically once daily for 8 weeks of treatment.

Interventions

QR-313

QR-313 will be applied topically once daily for 8 weeks of treatment.

Intervention Type: DRUG

Placebo

Placebo will be applied topically once daily for 8 weeks of treatment.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female, ≥ 4 years of age at Screening with a clinical diagnosis of DDEB or RDEB and at least one pathogenic mutation in exon 73 of the COL7A1 gene.

2. Have at least one TWA, ie, a skin area of 7 x 7 cm that ishows no signs of local infection, and contains a target wound that is either new or shows dynamic wound healing and complies to the following additional criteria:

1. surface area of the target wound ranging from 5 to 30 cm2, located centrally in the selected 7 x 7 cm TWA.

2. exposed sub-epidermal tissue to allow absorption of the IMP.

3. no suspicion of current squamous cell carcinoma (SCC) upon visual inspection.

Exclusion Criteria

1. Pregnant or breast-feeding female

2. Hemoglobin level at Screening requiring transfusion. The subject may be rescreened when the condition is considered stable.

3. Use of aminoglycosides, by any route of administration, except eye drops, 7 days or 5 half-lives, whichever is longer, prior to Baseline visit.

4. Untreated carcinoma of the TWA or history of carcinoma within 5 years prior to Screening, except adequately treated cutaneous squamous or basal cell carcinoma.

5. Life expectancy less than 6 months, as assessed by the Investigator

6. Current or known history of clinically significant hepatic or renal disease, that in the opinion of the Investigator, could impact subject safety or study participation.

7. Treatment with any systemic immunomodulators, immunosuppressants or cytotoxic chemotherapy within 2 months prior to the Baseline visit.

8. Use of any investigational drug or device within 28 days or 5 half-lives of the Baseline visit, whichever is longer, or plans to participate in another study of a drug or device during the study period. The washout of 5 half-lives does not apply to gene and cell therapy.

9. Known hypersensitivity to oligonucleotide treatment or excipients of the IMP.

10. Bleeding disorder or condition requiring the use of anticoagulants to be confirmed by aPTT by local lab within 48 hours of first treatment.

11. Use of systemic or topical steroids within 1 month prior to the baseline visit (inhaled and ophthalmic drops of corticosteroids or low dose topical solution of budesonide for esophagial strictures may be allowed).

• Minimum Eligible Age: 4 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Phoenicis Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Operations

Role: STUDY_DIRECTOR

Phoenicis Therapeutics

Locations

Stanford University School of Medicine, LPCH

Palo Alto, California, United States

Children's Hospital Colorado

Aurora, Colorado, United States

Journey Clinic, Center for Pediatric Blood and Marrow Transplantation

Minneapolis, Minnesota, United States

Cincinnati Children's Hospital

Cincinnati, Ohio, United States

Hopital Necker Enfants Malades

Paris, , France

Hospital Universitario La Paz

Madrid, , Spain

Countries

United States; France; Spain

References

Miah KM, Hyde SC, Gill DR. Emerging gene therapies for cystic fibrosis. Expert Rev Respir Med. 2019 Aug;13(8):709-725. doi: 10.1080/17476348.2019.1634547. Epub 2019 Jun 27.

Reference Type: DERIVED

PMID: 31215818 (View on PubMed)

Other Identifiers

2017-004806-17

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

PQ-313-002

Identifier Type: -

Identifier Source: org_study_id